Back to Innovators

Diabetic foot ulcers (DFUs) and subsequent amputation incur enormous health and economic burdens to patients, healthcare systems, and societies. Along with the increase in the diabetic population, the global prevalence of diabetic foot ulcers has been 6.3% among DM patients, which means more than 30 million patients are living with an ulcer. DFU is the main complication that leads to a high disability rate of diabetes and can be life-threatening in severe cases. A lack of pharmacological therapeutic approaches successfully addressed DFUs in the past 20 years. As a novel macrophage-regulating drug, FESPIXON® is a breakthrough treatment for DFUs with proven significant efficacy among patients with DFUs in clinical trials and the real world. It is believed that Fespixon® will be able to promote the healing of foot ulcers of those patients and thereby reduce amputation and prevent disability.